 AUSTIN, Texas, Sept. 9, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in transforming care through genetic and cell-free DNA cfDNA testing, today announced the launch of Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values the quantity of donor-derived cfDNA dd-cfDNA, fraction of dd-cfDNA and total cfDNA on every report. 